Pharmaceuticals in Hungary
Datamonitor, January 2011, Pages: 40
The Pharmaceuticals in Hungary industry profile is an essential resource for top-level data and analysis covering the Pharmaceuticals industry. It includes data on market size and segmentation, plus textual and graphical analysis of the key trends and competitive landscape, leading companies and demographic information.
Scope
- Contains an executive summary and data on value, volume and/or segmentation
- Provides textual analysis of Pharmaceuticals in Hungary’s recent performance and future prospects
- Incorporates in-depth five forces competitive environment analysis and scorecards
- Includes a five-year forecast of Pharmaceuticals in Hungary
- The leading companies are profiled with supporting key financial metrics
- Supported by the key macroeconomic and demographic data affecting the market
Highlights
- Detailed information is included on market size, measured by value and/or volume
- Five forces scorecards provide an accessible yet in depth view of the market’s competitive landscape
- Market shares are covered by manufacturer or brand
Why you should buy this report
- Spot future trends and developments
- Inform your business decisions
- Add weight to presentations and marketing materials
- Save time carrying out entry-level research
Market Definition
The pharmaceuticals market consists of ethical drugs only and does not include consumer healthcare or animal healthcare. Market values have been calculated at ex-factory prices (the value at which manufacturers sell the drugs to distributors). Any currency conversions used in the production of this report have been calculated at constant annual average exchange rates. For the purpose of this report Europe is deemed to comprise of Belgium, the Czech Republic, Denmark, France, Germany, Hungary, Italy, Netherlands, Norway, Poland, Romania, Russia, Spain, Sweden, the Ukraine and the United Kingdom.
EXECUTIVE SUMMARY
MARKET OVERVIEW
Market definition
Research highlights
Market analysis
MARKET VALUE
MARKET SEGMENTATION I
MARKET SEGMENTATION II
MARKET SHARE
FIVE FORCES ANALYSIS
Summary
Buyer power
Supplier power
New entrants
Substitutes
Rivalry
LEADING COMPANIES
EGIS Pharmaceuticals Plc
Gedeon Richter Plc
Novartis AG
MARKET FORECASTS
Market value forecast
MACROECONOMIC INDICATORS
APPENDIX
Methodology
Industry associations
Related Datamonitor research
Disclaimer
ABOUT DATAMONITOR
Premium Reports
Summary Reports
Datamonitor consulting
LIST OF TABLES
Table 1: Hungary pharmaceuticals market value: $ billion, 2006–10(e)
Table 2: Hungary pharmaceuticals market segmentation I:% share, by value, 2010(e)
Table 3: Hungary pharmaceuticals market segmentation II: % share, by value, 2010(e)
Table 4: Hungary pharmaceuticals market share: % share, by value, 2010(e)
Table 5: EGIS Pharmaceuticals Plc: key facts
Table 6: EGIS Pharmaceuticals Plc: key financials ($)
Table 7: EGIS Pharmaceuticals Plc: key financials (HUF)
Table 8: EGIS Pharmaceuticals Plc: key financial ratios
Table 9: Gedeon Richter Plc: key facts
Table 10: Gedeon Richter Plc: key financials ($)
Table 11: Gedeon Richter Plc: key financials (HUF)
Table 12: Gedeon Richter Plc: key financial ratios
Table 13: Novartis AG: key facts
Table 14: Novartis AG: key financials ($)
Table 15: Novartis AG: key financial ratios
Table 16: Hungary pharmaceuticals market value forecast: $ billion, 2010–15
Table 17: Hungary size of population (million), 2006–10
Table 18: Hungary GDP (constant 2000 prices, $ billion), 2006–10
Table 19: Hungary GDP (current prices, $ billion), 2006–10
Table 20: Hungary inflation, 2006–10
Table 21: Hungary consumer price index (absolute), 2006–10
Table 22: Hungary exchange rate, 2006–10
LIST OF FIGURES
Figure 1: Hungary pharmaceuticals market value: $ billion, 2006–10(e)
Figure 2: Hungary pharmaceuticals market segmentation I:% share, by value, 2010(e)
Figure 3: Hungary pharmaceuticals market segmentation II: % share, by value, 2010(e)
Figure 4: Hungary pharmaceuticals market share: % share, by value, 2010(e)
Figure 5: Forces driving competition in the pharmaceuticals market in Hungary, 2010
Figure 6: Drivers of buyer power in the pharmaceuticals market in Hungary, 2010
Figure 7: Drivers of supplier power in the pharmaceuticals market in Hungary, 2010
Figure 8: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Hungary, 2010
Figure 9: Factors influencing the threat of substitutes in the pharmaceuticals market in Hungary, 2010
Figure 10: Drivers of degree of rivalry in the pharmaceuticals market in Hungary, 2010
Figure 11: EGIS Pharmaceuticals Plc: revenues & profitability
Figure 12: EGIS Pharmaceuticals Plc: assets & liabilities
Figure 13: Gedeon Richter Plc: revenues & profitability
Figure 14: Gedeon Richter Plc: assets & liabilities
Figure 15: Novartis AG: revenues & profitability
Figure 16: Novartis AG: assets & liabilities
Figure 17: Hungary pharmaceuticals market value forecast: $ billion, 2010–15
- EGIS Pharmaceuticals Plc
- Gedeon Richter Ltd
- Novartis AG
- Sanofi-Aventis
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
